Discriminative-stimulus effects of cannabidiol oil in Sprague-Dawley rats.

Publisher: Lippincott Williams and Wilkins Country of Publication: England NLM ID: 9013016 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5849 (Electronic) Linking ISSN: 09558810 NLM ISO Abbreviation: Behav Pharmacol Subsets: MEDLINE

Publication: London : Lippincott Williams and Wilkins
Original Publication: London : Clinical Neuroscience Publishers,

Cannabidiol*/pharmacology; Rats ; Male ; Animals ; Rats, Sprague-Dawley ; Chlordiazepoxide/pharmacology ; Discrimination Learning ; Benzodiazepines/pharmacology

Cannabidiol (CBD) is one of the major centrally active phytocannabinoid components of cannabis, and has been approved by the FDA only for the treatment of seizures associated with three rare disorders. It has also been touted as a potential treatment for anxiety in place of more traditional treatments like benzodiazepines. Although there is some evidence of anxiolytic effects of CBD, its suitability as a substitute for benzodiazepines is unknown. This experiment was designed to assess the extent to which CBD shares interoceptive discriminative-stimulus properties with the anxiolytic drug chlordiazepoxide (CDP), a benzodiazepine. In the present experiment, a range of doses (0-1569 mg/kg) of over-the-counter CBD oil was administered (i.g.) in male Sprague-Dawley rats trained to discriminate 5.6 mg/kg CDP from saline. Due to the long time-course effects of CBD, generalization tests were conducted at 90 and 120 min post-CBD administration. The two highest doses of CBD tested (1064 and 1569 mg/kg) were found to partially substitute for 5.6 mg/kg CDP, with mean percent responding on the CDP-associated lever reaching above 20% at time 2 (120 min post-CBD administration), suggesting that high doses of the over-the-counter CBD oils used in this experiment share interoceptive discriminative-stimulus properties to some degree with CDP. These results are novel in comparison to existing research into stimulus effects of CBD, in which substitution for benzodiazepines has not previously been observed.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Behav Brain Res. 2006 Sep 25;172(2):294-8. (PMID: 16780966)
Pharmacol Res. 2017 May;119:358-370. (PMID: 28249817)
Drug Alcohol Depend. 2015 Jun 1;151:284-8. (PMID: 26207268)
J Exp Anal Behav. 1962 Oct;5:529-30. (PMID: 13945507)
Cannabis Cannabinoid Res. 2018 Jul 01;3(1):152-161. (PMID: 30014038)
Trends Pharmacol Sci. 2018 Jul;39(7):659-671. (PMID: 29716746)
J Exp Anal Behav. 2019 Mar;111(2):192-206. (PMID: 30758051)
Int J Mol Sci. 2021 Dec 22;23(1):. (PMID: 35008517)
Epilepsy Behav. 2022 Apr;129:108615. (PMID: 35217387)
Epilepsy Behav. 2018 Sep;86:131-137. (PMID: 30006259)
Drug Alcohol Depend. 2021 Aug 1;225:108827. (PMID: 34186444)
Trends Pharmacol Sci. 2009 Oct;30(10):515-27. (PMID: 19729208)
Epilepsia. 2018 Nov;59(11):2106-2117. (PMID: 30306542)
Eur Neuropsychopharmacol. 2017 Dec;27(12):1223-1237. (PMID: 29129557)
Psychopharmacology (Berl). 2021 Jan;238(1):9-28. (PMID: 33221931)
Epilepsy Behav. 2019 Sep;98(Pt A):201-206. (PMID: 31382177)
Epilepsia. 2021 Sep;62(9):2228-2239. (PMID: 34287833)
Psychopharmacology (Berl). 1998 Jul;138(1):67-75. (PMID: 9694528)
Psychopharmacology (Berl). 2012 Feb;219(3):859-73. (PMID: 21796370)
J Cannabis Res. 2021 Feb 18;3(1):5. (PMID: 33602344)
Pharmacol Biochem Behav. 2009 Apr;92(2):297-303. (PMID: 19159643)
Clin Pharmacol Ther. 2019 Jun;105(6):1395-1406. (PMID: 30912119)
Psychopharmacology (Berl). 1989;97(4):466-70. (PMID: 2567029)
J Cannabis Res. 2022 Jun 6;4(1):28. (PMID: 35658956)
Lancet. 2018 Mar 17;391(10125):1085-1096. (PMID: 29395273)
Behav Res Methods. 2017 Aug;49(4):1494-1502. (PMID: 27620283)
Braz J Psychiatry. 2019 Jan-Mar;41(1):9-14. (PMID: 30328956)
Neurosci Biobehav Rev. 1994 Spring;18(1):85-95. (PMID: 8170624)
J Pharmacol Exp Ther. 1990 Jun;253(3):1002-9. (PMID: 2162942)
Epilepsy Behav. 2022 Feb;127:108514. (PMID: 34998268)
Sci Total Environ. 2022 Dec 10;851(Pt 1):158110. (PMID: 35987236)
Biomolecules. 2020 Nov 19;10(11):. (PMID: 33228239)
J Toxicol Sci. 2018;43(7):451-458. (PMID: 29973477)
N Engl J Med. 2017 May 25;376(21):2011-2020. (PMID: 28538134)
JAMA. 2017 Nov 7;318(17):1708-1709. (PMID: 29114823)
Pain. 2019 Jan;160(1):136-150. (PMID: 30157131)
Handb Exp Pharmacol. 2008;(182):335-60. (PMID: 18175099)
Pharmacol Res Perspect. 2020 Dec;8(6):e00682. (PMID: 33169541)
Epilepsia. 2019 Nov;60(11):2224-2234. (PMID: 31625159)
J Clin Pharmacol. 2002 Nov;42(S1):11S-19S. (PMID: 12412831)
Pharmacol Biochem Behav. 1999 Oct;64(2):439-44. (PMID: 10515327)
J Exp Anal Behav. 2018 Mar;109(2):293-312. (PMID: 29473961)
Pharmacopsychiatry. 1993 May;26 Suppl 1:2-9. (PMID: 8378418)
Cannabis Cannabinoid Res. 2018 Sep 27;3(1):190-194. (PMID: 30283822)
P T. 2010 Jul;35(7):392-415. (PMID: 20689626)
Eur J Pharmacol. 1999 Oct 8;382(2):69-74. (PMID: 10528140)
J Pharmacol Exp Ther. 2022 Jul;382(1):54-65. (PMID: 35489780)
Psychopharmacology (Berl). 1990;100(4):558-9. (PMID: 1969666)
Neuropsychopharmacology. 2023 Oct;48(11):1612-1622. (PMID: 37142665)
Br J Pharmacol. 2006 Aug;148(7):984-90. (PMID: 16783415)
Pharmacol Ther. 1990;47(2):267-80. (PMID: 1975445)

T32 DA007294 United States DA NIDA NIH HHS

19GBJ60SN5 (Cannabidiol)
6RZ6XEZ3CR (Chlordiazepoxide)
12794-10-4 (Benzodiazepines)

Date Created: 20231212 Date Completed: 20240221 Latest Revision: 20240309

20240309

PMC10922827

10.1097/FBP.0000000000000762

38085665